NVS · NYSE
Novartis AG
$151.50 -4.76 (-3.05%)
Company overview
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines, active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties, and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Market cap
- $288B
- Employees
- 75,883
- Headquarters
- Basel
- Website
- novartis.com
- CEO
- Vasant Narasimhan
- Listed
- November 7, 1996
- P/E
- 21.58
- Dividend yield
- 3.04%
Company financials
- Revenue
- $56.1B
- Gross profit
- $42.2B
- Operating income
- $17.1B
- EBITDA
- $22.4B
- Net income
- $13.5B
- EPS
- $7.02
- Total assets
- $119B
- Total debt
- $47B
- Gross margin
- 75.27%
- Net margin
- 24.14%
- Earnings yield
- 4.63%
Showing FY 2022
NVS
1D
NYSE
O154.90H157.10L154.38C156.27+2.34 (+1.52%)Vol2.08M